EuroSIDA Publications 2022
 
  1. Integrase Strand Transfer Inhibitor Use and Cancer Incidence in a Large Cohort Setting. Greenberg L, Ryom L, Neesgaard B, Miró JM, Dahlerup Rasmussen L, Zangerle R, Grabmeier-Pfistershammer K, Günthard HF, Kusejko K, Smith C, Mussini C, Menozzi M, Wit F, Van Der Valk M, d'Arminio Monforte A, De Wit S, Necsoi C, Pelchen-Matthews A, Lundgren J, Peters L, Castagna A, Muccini C, Vehreschild JJ, Pradier C, Bruguera Riera A, Sönnerborg A, Petoumenos K, Garges H, Rogatto F, Dedes N, Bansi-Matharu L, Mocroft A; RESPOND Study Group.
    Open Forum Infect Dis. 2022;9(3):ofac029. Abstract
     
  2. Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium. Byonanebye DM, Polizzotto MN, Neesgaard B, Sarcletti M, Matulionyte R, Braun DL, Castagna A, de Wit S, Wit F, Fontas E, Vehreschild JJ, Vesterbacka J, Greenberg L, Hatleberg C, Garges H, Gallant J, Volny Anne A, Öllinger A, Mozer-Lisewska I, Surial B, Spagnuolo V, Necsoi C, van der Valk M, Mocroft A, Law M, Ryom L, Petoumenos K; RESPOND study group.
    HIV Med. 2022. Epub ahead of print. Abstract
     
Total publications February 2022: 322

 

​IN PRESS

  1. Association between Integrase Strand Transfer Inhibitors and Cardiovascular Disease in People Living with HIV: A Multicentered Prospective Study from the RESPOND Cohort Consortium. Lancet HIV. 2022